A Phase 2 interventional study of Sorafenib and BIBF 1120 in Carcinoma, Hepatocellular, sponsored by Boehringer Ingelheim. Completed at 28 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-26.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Carcinoma, Hepatocellular with a site in Germany — 23 open to participants now, 38 under way, 9 of them phase 3. Carcinoma, Hepatocellular · Germany.
Among the 149 studies in Carcinoma, Hepatocellular with a site in Germany, this one is the 64th largest by enrollment of the 124 interventional ones that give a count, is one of 6 that started in 2009, is one of 43 in phase 2, and was the 26th registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.
Browse Carcinoma, Hepatocellular studies →23 of the 149 studies in Carcinoma, Hepatocellular with a site in Germany are open now. Recruiting first, the newest first:
AIO-Studien-gGmbH · Sites in Germany
Ages 18+
RWTH Aachen University · Sites in Germany
Ages 18–80
CatalYm GmbH · Sites in Germany, United States, France and 4 more countries
Ages 18–100
Bristol-Myers Squibb · Sites in Germany, United States, Australia and 11 more countries
Ages 18+
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 59 · Phase 3 37 · Phase 4 4
First in 1999; this study’s year is marked. 6 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 125 is above the median of 54 across 2,620 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 128 across the 124 interventional studies, 250 across the 25 observational. Of the 101 that completed or were terminated, 43 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
98 of 149 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 3 studies filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
11 of the studies in Carcinoma, Hepatocellular with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03017326Phase 3University of BirminghamPaediatric Hepatic International Tumour Trial | 2026-12-31 |
| NCT04803994Phase 3Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestThe ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | 2027-07 |
| NCT05911633Terumo Europe N.V.BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC) | 2026-11-30 |
| NCT05844046Enrico De ToniSequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients | 2026-12-31 |
| NCT05176483ExelixisStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors | 2027-01-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 149 studies in Carcinoma, Hepatocellular with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aim is to determine maximally tolerated dose (MTD) of BIBF 1120 in HCC (hepatocellular cancer) and compare efficacy of BIBF 1120 to Sorafenib in HCC patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase I dose escalation and phase II using dose determined in phase I ( 200 mg BID)
Drug: BIBF 1120
Drug: Sorafenib
Maximum Tolerated Dose in Phase I
The MTD was defined as the highest dose studied for which the incidence of dose limiting toxicities (DLTs) was 0/3 or less than 2/6 patients during the first treatment course.
Time frame: 4 weeks
Time to Progression (TTP) in Phase II
TTP according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.0 criteria based on central independent review. TTP RECIST 1.0 was defined as the time from randomisation to disease progression according to RECIST 1.0.
Time frame: From randomization until data cut-off (15 July 2014); Up to 1031 days
Incidence of Dose Limiting Toxicity in Phase I
Number of patients with dose limiting toxicity are presented
Time frame: 4 weeks
Objective Tumour Response by RECIST
Objective RECIST 1.0 tumour response was defined as Complete Response (CR) or Partial Response (PR) and was derived from the patient's best objective RECIST 1.0 response based on central independent review. 95% Confidence Interval presented below are computed by Clopper and Pearson method.
Time frame: From randomization until data cut-off (15 July 2014); Up to 1031 days
Progression Free Survival (PFS)
PFS by RECIST 1.0 was defined as the duration from date of randomisation to date of progression or death, whichever occurred earlier, based on central independent review.
Time frame: From randomization until data cut-off (15 July 2014); Up to 1031 days
Overall Survival
Overall survival was defined as the duration from date of randomisation to the date of death.
Time frame: From randomization until data cut-off (15 July 2014); Up to 1031 days
| Milestone | Phase 1 Group 1, 100mg Nintedanib Bid | Phase I Group 1, 150mg Nintedanib Bid | Phase I Group 1, 200mg Nintedanib Bid | Phase I Group 2, 50mg Nintedanib Bid | Phase I Group 2, 100mg Nintedanib Bid | Phase I Group 2, 150mg Nintedanib Bid | Phase I Group 2, 200mg Nintedanib Bid | Phase II, 200 mg Nintedanib Bid | Phase II, 400 mg Sorafenib Bid |
|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 3 | 4 | 3 | 4 | 4 | 8 | 62 | 31 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
| Not completed | 6 | 3 | 4 | 3 | 4 | 4 | 8 | 60 | 30 |
| Withdrew: Progressive disease | 2 | 1 | 1 | 0 | 2 | 1 | 1 | 39 | 22 |
| Withdrew: Adverse event | 4 | 2 | 3 | 3 | 2 | 2 | 7 | 21 | 6 |
| Withdrew: Refused to continue taking trial med. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
The MTD was defined as the highest dose studied for which the incidence of dose limiting toxicities (DLTs) was 0/3 or less than 2/6 patients during the first treatment course.
| mg bid | Group 1 | Group 2 |
|---|---|---|
| Maximum Tolerated Dose in Phase I | 200 | 200 |
TTP according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.0 criteria based on central independent review. TTP RECIST 1.0 was defined as the time from randomisation to disease progression according to RECIST 1.0.
| months | Phase II, 200 mg Nintedanib Bid | Phase II, 400 mg Sorafenib Bid |
|---|---|---|
| Time to Progression (TTP) in Phase II | 5.45 (2.69 to 9.20) | 4.63 (2.79 to 20.40) |
Number of patients with dose limiting toxicity are presented
| participants | Phase I Group I, 100 mg Nintedanib Bid | Phase I Group 1, 150 mg Nintedanib Bid | Phase I Group 1, 200 mg Nintedanib Bid | Phase I Group 2, 50 mg Nintedanib Bid | Phase I Group 2, 100 mg Nintedanib Bid | Phase I Group 2, 150 mg Nintedanib Bid | Phase I Group 2, 200 mg Nintedanib Bid |
|---|---|---|---|---|---|---|---|
| Incidence of Dose Limiting Toxicity in Phase I | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Objective RECIST 1.0 tumour response was defined as Complete Response (CR) or Partial Response (PR) and was derived from the patient's best objective RECIST 1.0 response based on central independent review. 95% Confidence Interval presented below are computed by Clopper and Pearson method.
| percentage of participants | Phase II, 200 mg Nintedanib Bid | Phase II, 400 mg Sorafenib Bid |
|---|---|---|
| Objective Tumour Response by RECIST | 1.6 (0.0 to 8.7) | 6.5 (0.8 to 21.4) |
PFS by RECIST 1.0 was defined as the duration from date of randomisation to date of progression or death, whichever occurred earlier, based on central independent review.
| months | Phase II, 200 mg Nintedanib Bid | Phase II, 400 mg Sorafenib Bid |
|---|---|---|
| Progression Free Survival (PFS) | 5.32 (2.69 to 9.20) | 3.94 (2.33 to 7.36) |
Overall survival was defined as the duration from date of randomisation to the date of death.
| months | Phase II, 200 mg Nintedanib Bid | Phase II, 400 mg Sorafenib Bid |
|---|---|---|
| Overall Survival | 11.86 (6.60 to 25.46) | 11.40 (6.51 to 17.25) |
Collected over From first administration of the trial drug and until 28 days after the last administration of nintedanib or sorafenib, up to 1289 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1 Group 1, 100mg Nintedanib Bid | — | 3/6 (50%) | 6/6 (100%) |
| Phase I Group 1, 150mg Nintedanib Bid | — | 1/3 (33.3%) | 3/3 (100%) |
| Phase I Group 1, 200mg Nintedanib Bid | — | 4/4 (100%) | 4/4 (100%) |
| Phase I Group 2, 50mg Nintedanib Bid | — | 3/3 (100%) | 3/3 (100%) |
| Phase I Group 2, 100mg Nintedanib Bid | — | 2/4 (50%) | 4/4 (100%) |
| Phase I Group 2, 150mg Nintedanib Bid | — | 3/4 (75%) | 4/4 (100%) |
| Phase I Group 2, 200mg Nintedanib Bid | — | 4/8 (50%) | 7/8 (87.5%) |
| Phase II, 200 mg Nintedanib Bid | — | 34/62 (54.8%) | 61/62 (98.4%) |
| Phase II, 400 mg Sorafenib Bid | — | 14/31 (45.2%) | 31/31 (100%) |
| Event | Phase 1 Group 1, 100mg Nintedanib Bid | Phase I Group 1, 150mg Nintedanib Bid | Phase I Group 1, 200mg Nintedanib Bid | Phase I Group 2, 50mg Nintedanib Bid | Phase I Group 2, 100mg Nintedanib Bid | Phase I Group 2, 150mg Nintedanib Bid | Phase I Group 2, 200mg Nintedanib Bid | Phase II, 200 mg Nintedanib Bid | Phase II, 400 mg Sorafenib Bid |
|---|---|---|---|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/6 | 0/3 | 0/4 | 2/3 | 1/4 | 1/4 | 0/8 | 1/62 | 0/31 |
| AscitesGastrointestinal disorders | 1/6 | 0/3 | 0/4 | 2/3 | 0/4 | 0/4 | 1/8 | 1/62 | 0/31 |
| NauseaGastrointestinal disorders | 0/6 | 0/3 | 0/4 | 0/3 | 1/4 | 2/4 | 0/8 | 1/62 | 0/31 |
| VomitingGastrointestinal disorders | 0/6 | 0/3 | 0/4 | 1/3 | 1/4 | 2/4 | 1/8 | 1/62 | 0/31 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/6 | 0/3 | 0/4 | 1/3 | 0/4 | 2/4 | 0/8 | 2/62 | 3/31 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/6 | 1/3 | 0/4 | 0/3 | 0/4 | 0/4 | 0/8 | 1/62 | 0/31 |
| Rectal haemorrhageGastrointestinal disorders | 0/6 | 0/3 | 0/4 | 1/3 | 0/4 | 0/4 | 0/8 | 0/62 | 0/31 |
| Varices oesophagealGastrointestinal disorders | 0/6 | 0/3 | 0/4 | 1/3 | 0/4 | 0/4 | 1/8 | 1/62 | 1/31 |
| PyrexiaGeneral disorders | 0/6 | 0/3 | 0/4 | 1/3 | 0/4 | 0/4 | 0/8 | 0/62 | 1/31 |
| Bile duct obstructionHepatobiliary disorders | 0/6 | 1/3 | 0/4 | 0/3 | 0/4 | 0/4 | 0/8 | 0/62 | 1/31 |
| Event | Phase 1 Group 1, 100mg Nintedanib Bid | Phase I Group 1, 150mg Nintedanib Bid | Phase I Group 1, 200mg Nintedanib Bid | Phase I Group 2, 50mg Nintedanib Bid | Phase I Group 2, 100mg Nintedanib Bid | Phase I Group 2, 150mg Nintedanib Bid | Phase I Group 2, 200mg Nintedanib Bid | Phase II, 200 mg Nintedanib Bid | Phase II, 400 mg Sorafenib Bid |
|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/6 | 2/3 | 3/4 | 3/3 | 2/4 | 3/4 | 5/8 | 43/62 | 21/31 |
| NauseaGastrointestinal disorders | 1/6 | 3/3 | 3/4 | 2/3 | 1/4 | 3/4 | 7/8 | 29/62 | 9/31 |
| VomitingGastrointestinal disorders | 2/6 | 3/3 | 3/4 | 2/3 | 2/4 | 1/4 | 5/8 | 23/62 | 9/31 |
| Abdominal distensionGastrointestinal disorders | 1/6 | 0/3 | 3/4 | 0/3 | 1/4 | 0/4 | 1/8 | 1/62 | 1/31 |
| FatigueGeneral disorders | 3/6 | 0/3 | 3/4 | 2/3 | 1/4 | 2/4 | 5/8 | 32/62 | 10/31 |
| Influenza like illnessGeneral disorders | 1/6 | 1/3 | 3/4 | 1/3 | 0/4 | 1/4 | 0/8 | 1/62 | 0/31 |
| Decreased appetiteMetabolism and nutrition disorders | 1/6 | 0/3 | 3/4 | 0/3 | 2/4 | 2/4 | 5/8 | 23/62 | 13/31 |
| DyspepsiaGastrointestinal disorders | 1/6 | 2/3 | 0/4 | 0/3 | 1/4 | 0/4 | 1/8 | 1/62 | 1/31 |
| Aspartate aminotransferase increasedInvestigations | 0/6 | 2/3 | 0/4 | 0/3 | 0/4 | 0/4 | 2/8 | 11/62 | 5/31 |
| Blood alkaline phosphatase increasedInvestigations | 0/6 | 2/3 | 0/4 | 0/3 | 1/4 | 0/4 | 0/8 | 6/62 | 2/31 |
Treated set which included all patients who received at least one single dose of trial medication.
| Age, Continuous(Years) | Phase 1 Group 1, 100mg Nintedanib Bid | Phase I Group 1, 150mg Nintedanib Bid | Phase I Group 1, 200mg Nintedanib Bid | Phase I Group 2, 50mg Nintedanib Bid | Phase I Group 2, 100mg Nintedanib Bid | Phase I Group 2, 150mg Nintedanib Bid | Phase I Group 2, 200mg Nintedanib Bid | Phase II, 200 mg Nintedanib Bid | Phase II, 400 mg Sorafenib Bid | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 69.7 ± 6.8 | 65.0 ± 7.8 | 66.5 ± 4.0 | 72.3 ± 11.7 | 56.3 ± 6.4 | 59.3 ± 13.9 | 57.0 ± 11.0 | 65.4 ± 10.0 | 63.1 ± 11.8 | 64.2 ± 10.5 |
| Sex: Female, Male(Participants) | Phase 1 Group 1, 100mg Nintedanib Bid | Phase I Group 1, 150mg Nintedanib Bid | Phase I Group 1, 200mg Nintedanib Bid | Phase I Group 2, 50mg Nintedanib Bid | Phase I Group 2, 100mg Nintedanib Bid | Phase I Group 2, 150mg Nintedanib Bid | Phase I Group 2, 200mg Nintedanib Bid | Phase II, 200 mg Nintedanib Bid | Phase II, 400 mg Sorafenib Bid | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 1 | 0 | 0 | 0 | 1 | 2 | 14 | 5 | 24 |
| Male | 5 | 2 | 4 | 3 | 4 | 3 | 6 | 48 | 26 | 101 |
Ran from Oct 2009 to primary completion in Jul 2014, 56 months.
Results were first posted in Aug 2015, 1 year after primary completion. A results delay was requested in Aug 2014.
Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 56 months is above that.
Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nintedanib